|
Study (year) | Journal | Country | Inclusion/exclusion criteria | Patient number | Short-term outcome | Long-term outcome |
|
Leclerc et al. (2015) | Proceedings of the National Academy of Sciences of the United States of America | USA | Inclusion: >18 years, aSAH | Hp1-1: 11 Hp2-1: 39 Hp2-2: 24 | Clinical deterioration as a consequence of confirmed delayed cerebral ischemia | — |
Murthy et al. (2016) | Neurosurgery | USA | Inclusion: >18 years, aSAH presenting within 24 h of ictus Exclusion: death on arrival, pregnancy, inability to obtain consent | Hp1-1: 29 Hp2-1: 57 Hp2-2: 47 | Delayed cerebral ischemia defined as clinical deterioration with radiographic, angiographic, or clinical response to treatment with TCD evidence | GOS at 30 days post discharge |
Kantor et al. (2014) | Journal of Neurosurgery | USA | Inclusion: 18–75 years, angiographic diagnosis of aSAH, Fisher grade 2–4, Caucasian Exclusion: preexisting neurological disease or deficit | Hp1-1: 25 Hp2-1: 109 Hp2-2: 59 | — | mRS at 3 months |
Ohnishi et al. (2013) | Journal of Stroke and Cerebrovascular Diseases | Japan | Inclusion: aSAH treated endovascularly or surgically | Hp1-1: 7 Hp2-1: 39 Hp2-2: 49 | Delayed cerebral ischemia defined as development of focal neurology of a drop in GCS of 2 points | mRS at 3 months |
Galea et al. (2012) | Journal of Neurochemistry | UK | Inclusion: SAH requiring external ventricular drainage, paired CSF and serum available Exclusion: external ventricular drain infection | Hp1-1: 4 Hp2-1: 21 Hp2-2: 1 | Delayed cerebral ischemia defined as development of focal neurology of a drop in GCS of 2 points | — |
Borsody et al. (2006) | Neurology | USA | Inclusion: >18 years, known date onset SAH, aSAH suspected, Fisher grade 3-4 Exclusion: diseases which affect Hp or development of VS | Hp1-1: 9 Hp2-1: 12 Hp2-2: 11 | Transcranial Doppler (TCD) evidence of “presumed definite” vasospasm or angiogram evidence of vasospasm both by day 14 after SAH | — |
|